Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1
Year: 2017
Type: article
Institutions: Second Military Medical University, Shanghai Changzheng Hospital, Institute of Hematology & Blood Diseases Hospital, First Affiliated Hospital of Soochow University, Peking Union Medical College Hospital, Peking University People's Hospital, Guangdong Provincial People's Hospital, Xijing Hospital, Air Force Medical University, Shanghai Jiao Tong University, Ruijin Hospital, Takeda Oncology (United States), Dana-Farber Cancer Institute, Centre Hospitalier Universitaire de Nantes, Nantes Université
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2605622535